Biomaterial Database

Bronchiolitis in a rheumatoid arthritis patient receiving auranofin. 1986

J D O'Duffy, and H S Luthra, and K K Unni, and R E Hyatt

A patient with severe rheumatoid arthritis and sicca symptoms was treated with auranofin. During auranofin therapy, she developed irreversible airways obstruction due to bronchiolitis. Whereas this complication could have been due to her underlying disease, we discuss here the possibility of its being related to the auranofin therapy.

UI	MeSH Term	Description	Entries
D001991	Bronchitis	Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	Bronchitides
D005260	Female		Females
D006046	Gold	A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006051	Aurothioglucose	A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals.	Gold Thioglucose,Aureotan,Auromyose,Aurothioglucose, Sodium Salt, beta-D Isomer,Aurothioglucose, beta-D Isomer,Gold-50,Solganal,Solganal B Oleosum,Solganol,Thioglucosoaurate,Aurothioglucose, beta D Isomer,B Oleosum, Solganal,Gold 50,Gold50,Oleosum, Solganal B,Thioglucose, Gold,beta-D Isomer Aurothioglucose
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D001172	Arthritis, Rheumatoid	A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	Rheumatoid Arthritis
D001310	Auranofin	An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.	Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162